Cargando…

Metabolic syndrome: is equine disease comparable to what we know in humans?

This review summarizes similarities and differences between the metabolic syndromes in humans and equines, concerning the anatomy, symptoms, and pathophysiological mechanisms. In particular, it discusses the structure and distribution of adipose tissue and its specific metabolic pathways. Furthermor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ertelt, Antonia, Barton, Ann-Kristin, Schmitz, Robert R, Gehlen, Heidrun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068110/ https://www.ncbi.nlm.nih.gov/pubmed/24894908 http://dx.doi.org/10.1530/EC-14-0038

Ejemplares similares

Pulmonary Remodeling in Equine Asthma: What Do We Know about Mediators of Inflammation in the Horse?
por: Barton, Ann Kristin, et al.
Publicado: (2016)

Procalcitonin as a biomarker in equine chronic pneumopathies
por: Barton, Ann Kristin, et al.
Publicado: (2016)

Comparative Analysis of Intestinal Helminth Infections in Colic and Non-Colic Control Equine Patients
por: Gehlen, Heidrun, et al.
Publicado: (2020)

Are pulmonary hemostasis and fibrinolysis out of balance in equine chronic pneumopathies?
por: Barton, Ann Kristin, et al.
Publicado: (2017)

Metabolic syndrome: what we know and what we need to know
por: Soares, Raquel
Publicado: (2020)

Metalloproteinases and their inhibitors are influenced by inhalative glucocorticoid therapy in combination with environmental dust reduction in equine recurrent airway obstruction
por: Barton, Ann Kristin, et al.
Publicado: (2016)

Metalloproteinases and their Inhibitors under the Course of Immunostimulation by CPG-ODN and Specific Antigen Inhalation in Equine Asthma
por: Barton, Ann Kristin, et al.
Publicado: (2019)

Equine Crofton Weed (Ageratina spp.) Pneumotoxicity: What Do We Know and What Do We Need to Know?
por: Shapter, Frances Marie, et al.
Publicado: (2023)

The origin of life: what we know, what we can know and what we will never know
por: Pross, Addy, et al.
Publicado: (2013)

A comparative survey of veterinarians, equine owners, and equine keepers regarding the knowledge and implementation of legal requirements in Germany for the use and documentation of veterinary medicines in equines intended for slaughter
por: Schneider, Shary Tamara, et al.
Publicado: (2023)

Human Extraintestinal Sarcocystosis: What We Know, and What We don’t Know
por: Harris, V. C., et al.
Publicado: (2015)

MMP-9 Concentration in Peritoneal Fluid Is a Valuable Biomarker Associated with Endotoxemia in Equine Colic
por: Barton, Ann Kristin, et al.
Publicado: (2021)

Quasicrystals: What do we know? What do we want to know? What can we know?
por: Steurer, Walter
Publicado: (2018)

COVID-19 and cardiovascular disease: What we know, what we think we know, and what we need to know
por: Dhawan, Rahul, et al.
Publicado: (2020)

International Trade and Investment and Food Systems: What We Know, What We Don’t Know, and What We Don’t Know We Don’t Know
por: Schram, Ashley, et al.
Publicado: (2020)

Role of the Eye in Transmitting Human Coronavirus: What We Know and What We Do Not Know
por: Sun, Chuan-bin, et al.
Publicado: (2020)

The Influenza NS1 Protein: What Do We Know in Equine Influenza Virus Pathogenesis?
por: Barba, Marta, et al.
Publicado: (2016)

“Tau Oligomers,” What We Know and What We Don’t Know
por: Sahara, Naruhiko, et al.
Publicado: (2014)

Epigenetics in Schistosomes: What We Know and What We Need Know
por: Liu, Weiwei
Publicado: (2016)

Portion Size: What We Know and What We Need to Know
por: Benton, David
Publicado: (2015)

Paediatric schistosomiasis: What we know and what we need to know
por: Osakunor, Derick N. M., et al.
Publicado: (2018)

Immunotherapy and fatigue: what we know and what we don’t know
por: Azeem Khan, Muhammad, et al.
Publicado: (2021)

Vaginal Aging—What We Know and What We Do Not Know
por: Szymański, Jacek K., et al.
Publicado: (2021)

Complement and COVID-19: Three years on, what we know, what we don't know, and what we ought to know
por: Zelek, Wioleta M., et al.
Publicado: (2023)

What Do We Know About Neuropsychological Aspects Of Schizophrenia?
por: Palmer, Barton W., et al.
Publicado: (2009)

Commentary: Is this a case in which we know what we don't know what we don't know?
por: Nantsios, Alex, et al.
Publicado: (2021)

Gullo’s syndrome – what do we know?
por: Rycyk, Anna, et al.
Publicado: (2020)

Spectrum of MRI findings of foetal alcohol syndrome disorders—what we know and what we need to know!
por: Sharif, Saad, et al.
Publicado: (2023)

Asthma-COPD Overlap Syndrome: What We Know and What We Don't
por: Sin, Don D.
Publicado: (2017)

Nephrotoxicity testing in vitro--what we know and what we need to know.
por: Pfaller, W, et al.
Publicado: (1998)

Asthma in the elderly: what we know and what we have yet to know
por: Yáñez, Anahí, et al.
Publicado: (2014)

What We Know and What We Don't Know About Preventing Stroke
por: Burch, Druin
Publicado: (2014)

Contagious itch: what we know and what we would like to know
por: Schut, C., et al.
Publicado: (2015)

Goal-directed therapy: what we know and what we need to know
por: O’Neal, Jason B, et al.
Publicado: (2015)

Transmission of Ebola Viruses: What We Know and What We Do Not Know
por: Osterholm, Michael T., et al.
Publicado: (2015)

Membrane fission by dynamin: what we know and what we need to know
por: Antonny, Bruno, et al.
Publicado: (2016)

Microplastics in freshwater ecosystems: what we know and what we need to know
por: Wagner, Martin, et al.
Publicado: (2014)

Peri-implant disease: what we know and what we need to know
por: Valente, Nicola Alberto, et al.
Publicado: (2016)

Pneumonia in Bhutanese children: what we know, and what we need to know
por: Jullien, Sophie, et al.
Publicado: (2020)

Impacts of Neonicotinoids on Molluscs: What We Know and What We Need to Know
por: Ewere, Endurance E, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f39d8ik7cp87avv6iqfq7cpcs7